Posted on

Watershed moments in development

Podcast: Play in new window | Download

Subscribe: RSS

Autism diagnosis at 3 years of age isn’t something that happens suddenly. It evolves, there are deficits seen early on and markers that are evident prior to 3 years. Some of them are cascading events – with problems in one area like motor function, other behaviors like reaching, grasping, and learning about the environment and interactions with other people are stunted. Sometimes, these cascading moments lead to a loss of language. Early intervention can turn these early deficits around so that communication, learning and daily functioning are continually supported and instead of one trajectory, another can be reached. This podcast highlights studies that demonstrate that with data, and with theory. But it is never boiled down to one thing, despite early studies that screen time use is linked with an ASD diagnosis.

https://pubmed.ncbi.nlm.nih.gov/35098539/

https://pubmed.ncbi.nlm.nih.gov/35099540/

https://srcd.onlinelibrary.wiley.com/doi/abs/10.1111/cdep.12439

Posted on

“ASADHD” – where does ASD and ADHD join together, and go their separate ways?

Podcast: Play in new window | Download

Subscribe: RSS

One the surface, symptoms of ADHD and ASD may seem very similar.  However, they come from very different places.  The genetic and behavioral makeup may be on the same spectrum across the two disorders, but they are actually farther apart than you might think.  Dr. Meghan Miller from UC Davis MIND Institute who studies both ADHD and ASD and people with ADHD and ASD explains what those differences and similarities are, how to make the right diagnosis, and what’s on the horizon for treatments for ADHD in people with ASD.

 

https://www.ncbi.nlm.nih.gov/pubmed/31974800

https://www.ncbi.nlm.nih.gov/pubmed/30535156

https://www.ncbi.nlm.nih.gov/pubmed/30658861

Posted on

Can IGF-1 treat autism symptoms? A clinical trial aims to find out

Podcast: Play in new window | Download

Subscribe: RSS

A full transcript of this podcast episode can be read on the ASF blog here.

Researchers at Mount Sinai led by Alex Kolevzon are running a clinical trial of the compound insulin-like growth factor 1 (IGF-1) for children with idiopathic autism. Dr. Kolevzon’s team previously demonstrated the safety and feasibility of IGF-1 in treating Phelan-McDermid syndrome, a single-gene form of autism. Particularly, the IGF-1 treatment improved symptoms of social impairment and repetitive behaviors, which are core symptoms of autism. Expanding their investigation into idiopathic autism, the researchers are working hard to make sure families can comfortably and knowledgeably participate in the clinical trial. Mahir Rahman spoke with Dr. Kolevzon about the study and where it hopes to go. Interested in joining the study? Go here to learn more.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326443/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450831/